Search the Newsreel

Eupraxia Pharmaceuticals (EPRX) holders report around 4–5% stakes in 13G/A

An amended Schedule 13G filing for Eupraxia Pharmaceuticals (EPRX) reveals that Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank each report beneficial ownership of common shares ranging from approximately 4.1% to 4.5% of the …

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Marcio De'SouzaChief Financial Officer - Tim KellyPresident of Research and Development - Steve PetrouChief Operating Officer - Megan Sniecinski TAKEAWAYS Cash and …

Eupraxia reports symptom improvements in EoE trial analysis

Eupraxia Pharmaceuticals Inc. announced positive results from an analysis of its RESOLVE study, showing significant symptom improvements in eosinophilic esophagitis (EoE) patients treated with EP-104GI. The analysis revealed a substantial decrease in moderate to severe odynophagia and dysphagia, with severe symptoms dropping to zero …

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients

Eupraxia Pharmaceuticals announced positive symptom response data from its Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) patients. The analysis showed significant reductions in moderate to severe odynophagia (pain swallowing) and dysphagia (difficulty swallowing) lasting up to 52 weeks post-treatment, with no …

What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday?

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why

Praxis Precision Medicines (NASDAQ:PRAX) recently hit a new 52-week high of $382.97, driven by positive analyst sentiment, including maintained "Buy" ratings and high price targets from HC Wainwright and RBC. The company beat quarterly EPS expectations and is anticipated to have significant catalysts in …

Praxis Home Retail revises promoter reclassification disclosure

Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

EPRX Stock Price and Chart — TSX:EPRX

This article provides a detailed overview of Eupraxia Pharmaceuticals, Inc. (EPRX) stock on the Toronto Stock Exchange, including its current price, historical performance, key financial statistics, and analyst ratings. It highlights the company's focus on drug delivery technology for conditions like arthritis and chronic …

Eupraxia Q2 EPS beats estimate despite wider net loss

Eupraxia Pharmaceuticals Inc. reported Q2 2026 EPS of $(0.23), surpassing analyst estimates of $(0.25) despite a wider net loss of $14.5 million, primarily due to increased R&D spending for its lead EoE asset, EP-104GI. The company maintains strong liquidity with $133.6 million in cash …

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported a quarterly loss of $0.23 per share, surpassing analyst estimates by $0.02. Shares saw a modest increase of 0.6% to $6.70, and the company maintains strong financial liquidity. Analyst sentiment for EPRX is mixed but generally positive, with a "Moderate …

Eupraxia Pharmaceuticals (NASDAQ: EPRX) widens loss to $27.1M while raising $58.6M

Eupraxia Pharmaceuticals reported a widened net loss of $27.1 million for the six months ended June 30, 2026, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its liquidity by raising $58.6 million …

Equities Analysts Offer Predictions for PRAX Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS estimate for Praxis Precision Medicines (NASDAQ:PRAX) to a loss of $3.86 per share, maintaining a "Buy" rating and a $1,201 price target, indicating expectations for profitability by Q4 2027. Several other analysts also weighed in on …

H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201

H.C. Wainwright has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US), maintaining a target price of $1,201. This indicates continued confidence from the firm in the company's future performance.

Praxis Home Ret Standalone June 2026 Net Sales at Rs 26.60 crore, up 13.18% Y-o-Y

Can Praxis Precision Medicines' (PRAX) Extended Cash Runway Offset Mounting Losses In Its CNS Pipeline Push?

Will Eupraxia Pharmaceuticals Inc (EPRX) Beat Earnings Estimates in Its Next Report?

Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history

This page provides a comprehensive overview of Praxis Precision Medicines, Inc. (PRAX) stock, including its current price, historical data, key statistics, and company profile. It details the company's focus on developing therapies for CNS disorders and lists its pipeline of clinical-stage and preclinical drug …

Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances

Praxis Precision Medicines (PRAX) has achieved a significant milestone with its investigational treatment Elsunersen receiving FDA Breakthrough Therapy designation, advancing its central nervous system pipeline. Despite this regulatory success and other late-stage assets, the company reported substantial net losses and no meaningful revenue in …

Praxis Home Retail reports standalone net loss of Rs 11.06 crore in the June 2026 quarter

Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Eupraxia Pharmaceuticals Inc (EPRX), highlighting analyst ratings, target prices, and historical/projected EPS and revenue growth. Nine analysts currently rate EPRX as a "Buy" with a target price of USD 16.444, suggesting a 146.91% upside. The article also …

Eupraxia Pharmaceuticals Inc (EPRX) Stock News Today

This article provides current stock information for Eupraxia Pharmaceuticals Inc (EPRX), showing its stock price, market capitalization, and a brief overview of available financial data sections on the TradingKey platform. It indicates that more news regarding EPRX is expected soon. The content primarily serves …

Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside

Praxis Precision Medicines, Inc. (PRAX) has seen its average 12-month stock price target raised to $620.95 by 19 analysts, up from $604.83. This new target suggests a potential upside of approximately 95% from its recent closing price. The consensus analyst rating for PRAX remains …

Praxis Home Retail Q1FY27 loss narrows to ₹1,106.49 lakhs

Praxis Precision Medicines (NASDAQ:PRAX) Releases Quarterly Earnings Results, Beats Estimates By $0.80 EPS

Eupraxia Pharmaceuticals (NASDAQ: EPRX) sets up US$300M mixed securities shelf

Eupraxia Pharmaceuticals Inc. has filed a short form base shelf prospectus and accompanying Form F-10 to register up to US$300,000,000 in mixed securities, including common shares, preferred shares, debt securities, warrants, subscription receipts, and units. These securities may be offered over a 25-month period …

Praxis Precision Medicines (NASDAQ: PRAX) holds $1.4B cash, advances NDAs

Praxis Precision Medicines reported a Q2 2026 net loss of $83.7 million and a first-half loss of $176.3 million, driven by increased R&D and G&A expenses to fund clinical programs and commercial preparation. Despite these losses, the company holds $1.4 billion in cash, cash …

Praxis Precision Medicines gains as investors refocus on late-stage CNS pipeline and upcoming FDA catalysts

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Better-Than-Expected Earnings

Praxis Precision Medicines stock hits 52-week high at 366.7 USD

Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, reflecting a 557% one-year return and a market cap of $9.92 billion, despite an InvestingPro analysis suggesting it may be overvalued. The company recently reported a Q2 2026 loss of $2.87 …

Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss

Praxis Precision Medicines beats Q2 loss estimates; shares rise

Praxis Precision Medicines Inc. (NASDAQ:PRAX) reported a Q2 loss of $2.87 per share, outperforming analyst estimates. The company's shares rose 6.5% in premarket trading following the news, which also highlighted progress with FDA interactions for its drug candidates ulixacaltamide HCl and relutrigine, and a …

Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript